These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19111544)

  • 1. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
    Liu P; Xu B; Li J; Lu H
    FEBS Lett; 2009 Jan; 583(2):401-6. PubMed ID: 19111544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
    Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
    Ottosson-Wadlund A; Ceder R; Preta G; Pokrovskaja K; Grafström RC; Heyman M; Söderhäll S; Grandér D; Hedenfalk I; Robertson JD; Fadeel B
    Mol Pharmacol; 2013 Jan; 83(1):245-55. PubMed ID: 23093495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
    Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
    J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.
    Chen S; Blank JL; Peters T; Liu XJ; Rappoli DM; Pickard MD; Menon S; Yu J; Driscoll DL; Lingaraj T; Burkhardt AL; Chen W; Garcia K; Sappal DS; Gray J; Hales P; Leroy PJ; Ringeling J; Rabino C; Spelman JJ; Morgenstern JP; Lightcap ES
    Cancer Res; 2010 Jun; 70(11):4318-26. PubMed ID: 20460535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
    Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
    Wolter KG; Verhaegen M; Fernández Y; Nikolovska-Coleska Z; Riblett M; de la Vega CM; Wang S; Soengas MS
    Cell Death Differ; 2007 Sep; 14(9):1605-16. PubMed ID: 17541428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
    Fu YB; Sun QX; Meng FY; Xie J; Zhou GB
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2413-6. PubMed ID: 17156654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways.
    Rapino F; Jung M; Fulda S
    Oncogene; 2014 Mar; 33(13):1713-24. PubMed ID: 23644654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.
    Rumpold H; Salvador C; Wolf AM; Tilg H; Gastl G; Wolf D
    Biochem Biophys Res Commun; 2007 Sep; 361(2):549-54. PubMed ID: 17662692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
    Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
    Anan A; Baskin-Bey ES; Isomoto H; Mott JL; Bronk SF; Albrecht JH; Gores GJ
    Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
    Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
    Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.